• Ceftolozane/Tazobactam: Advancing Therapy for Resistant Infe

  2026-07-14

  The reference study introduces ceftolozane/tazobactam as a novel cephalosporin/b-lactamase inhibitor combination with enhanced efficacy against multidrug-resistant gram-negative organisms, including Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae. The paper highlights its unique pharmacokinetics, expanded antimicrobial spectrum, and clinical utility in treating complicated intraabdominal and urinary tract infections, emphasizing its significance in combating antimicrobial resistance.

• Applied Workflows with Live-Dead Cell Staining Kit I (Calcei

  2026-07-13

  The Live-Dead Cell Staining Kit I (Calcein AM/PI) enables precise, rapid, and reproducible fluorescence-based viability assessment in mammalian cells, streamlining advanced cytotoxicity and mechanistic workflows. This article details protocol upgrades, troubleshooting strategies, and unique use-cases to maximize the kit’s capabilities, including insights from recent oncology breakthroughs.

• Impact of Antiarrhythmic Drugs on Cardiac KCa2 Channels in A

  2026-07-13

  This study systematically investigates whether commonly used antiarrhythmic agents for atrial fibrillation, including Dronedarone (Multaq), modulate small conductance calcium-activated potassium (KCa2) channels. The findings reveal that most standard antiarrhythmic drugs do not meaningfully inhibit KCa2 channels at clinically relevant concentrations, influencing future directions for atrial-selective pharmacological strategies.

• E-4031 and the Next Horizon in 3D Cardiac Electrophysiology

  2026-07-12

  This thought-leadership article explores how E-4031, a selective hERG potassium channel blocker, is fueling a paradigm shift in cardiac electrophysiology research. Drawing on recent advances in 3D organoid modeling and next-generation microelectrode arrays, we dissect the mechanistic, experimental, and translational implications of precise hERG inhibition. The discussion synthesizes fresh evidence, including landmark 3D mapping studies, and delivers actionable guidance for translational researchers seeking to model proarrhythmic risk, optimize QT interval studies, and pioneer new frontiers in preclinical cardiac safety assessment.

• Cy3 NHS ester (non-sulfonated): Technical Guide for Protein

  2026-07-10

  Cy3 NHS ester (non-sulfonated) enables robust, high-sensitivity labeling of proteins, peptides, and oligonucleotides via primary amino groups, supporting quantitative imaging and detection where organic co-solvents are acceptable. Its performance is optimal in workflows using DMSO or DMF rather than water-only conditions. Researchers handling delicate proteins should consider water-soluble alternatives when co-solvents may compromise sample integrity.

• Mechanistic Dissection of Aneugenicity via Tiered Molecular

  2026-07-09

  The referenced study introduces a tiered molecular assay and advanced flow cytometry approach for classifying aneugenic agents by their molecular mechanism—distinguishing tubulin stabilizers, destabilizers, and mitotic kinase inhibitors. This innovation, validated across 27 chemicals, provides a robust framework for mechanistic genotoxicity profiling relevant to both toxicological research and antifungal drug discovery.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-07-09

  This study establishes that male and female mice exhibit markedly different blood pressure responses to chronic angiotensin II infusion, with males developing more severe hypertension. The findings highlight the essential roles of sex hormones and autonomic regulation in hypertension pathophysiology, offering a foundation for sex-specific cardiovascular research.

• Vemurafenib (PLX4032, RG7204): Reliable BRAF V600E Inhibitio

  2026-07-08

  This article explores scenario-driven laboratory challenges in melanoma research and demonstrates how Vemurafenib (PLX4032, RG7204), SKU A3004, addresses these with evidence-backed solutions. Researchers will gain insights into optimizing assay reproducibility, overcoming resistance, and streamlining workflows using this selective BRAF kinase inhibitor. Practical protocol guidance and candid product selection advice are provided to ensure experimental rigor.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Protocol and QC Gui

  2026-07-08

  The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables specific, high-sensitivity fluorescent detection of goat IgG in immunocytochemistry, immunohistochemistry, flow cytometry, and ELISA workflows. It should not be used with non-goat primary antibodies or outside validated immunodetection applications where Cy3-based fluorescence detection and signal amplification are required.

• L-Phenylephrine (SKU C3021): Empowering α1A Receptor Researc

  2026-07-07

  This article offers scenario-driven guidance for researchers leveraging L-Phenylephrine (SKU C3021) in cardiovascular and neural assay workflows. Drawing on peer-reviewed evidence and product specifications, it addresses common challenges in reproducibility, protocol design, and data interpretation, highlighting how APExBIO's high-purity L-Phenylephrine supports experimental reliability.

• Iptacopan (LNP023): Selective Factor B Inhibition for Comple

  2026-07-07

  Iptacopan (LNP023) is a potent, selective oral inhibitor of complement factor B that blocks alternative pathway C3bBb formation. Clinical and preclinical results show rapid and durable control of complement-mediated hemolysis, with high selectivity and efficacy in PNH and glomerulopathies. This dossier details Iptacopan's mechanism, validated benchmarks, and integration into complement activation research.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-07-06

  This study rigorously demonstrates sex-specific responses in the development of angiotensin II-induced hypertension in conscious mice, with male mice exhibiting a markedly greater hypertensive response compared to females. The findings offer mechanistic insight into the roles of sex hormones in blood pressure regulation and highlight important considerations for cardiovascular disease modeling.

• Azilsartan Medoxomil Monopotassium: Network Meta-Analysis in

  2026-07-06

  A recent network meta-analysis systematically compared the antihypertensive efficacy of azilsartan medoxomil (TAK 491) with other first-line agents in mild-to-moderate hypertension. The study demonstrates that azilsartan medoxomil, particularly at 80 mg, provides superior blood pressure reduction, setting a new benchmark for essential hypertension treatment research.

• Paroxetine Mesylate (C8698): Reliable SSRI for Cell Assays

  2026-07-05

  This article delivers a scenario-driven, evidence-based guide for biomedical researchers and lab technicians seeking robust, reproducible results in cell viability, proliferation, and cytotoxicity assays using Paroxetine Mesylate (SKU C8698). Drawing on validated protocol parameters and comparative analysis, it demonstrates how this selective serotonin reuptake inhibitor addresses key pain points, ensuring data quality and workflow efficiency.

• Acridine Orange hydrochloride: Technical Guide for Nucleic A

  2026-07-04

  Acridine Orange hydrochloride enables reliable differential staining of DNA and RNA in situ, supporting workflows like cell cycle analysis, apoptosis detection, and flow cytofluorometric nucleic acid staining. Its dual-fluorescence properties and membrane permeability make it suited for rapid, sensitive cytochemical assays. Avoid in applications requiring long-term solution storage or unsupported mechanistic interpretation.

444 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page